[1] Tanis E, Nordlinger B, Mauer M, et al. Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. Eur J Cancer, 2014, 50: 912-919. [2] Kumar SK, Oon OK, Horgan P, et al. Early Diagnosis of Intrahepatic Pseudoaneurysm during Radiofrequency Ablation using Contrast-Enhanced Ultrasound. Malays J Med Sci, 2015, 22: 58-62. [3] Oldhafer KJ, Donati M, Jenner RM, et al. ALPPS for patients with colorectal liver metastases: effective liver hypertrophy, but early tumor recurrence. World J Surg, 2014, 38: 1504-1509. [4] Mise Y, Aloia TA, Brudvik KW, et al. Parenchymal-sparing hepatectomy in colorectal liver metastasis improves salvage ability and survival. Ann Surg, 2016, 263:146-152. [5] Shindoh J, Truty MJ, Aloia TA, et al. Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant. J Am Coll Surg, 2013, 216: 201-209. [6] Allard MA, Cunha AS, Gayet B, et al. Early and Long-term Oncological Outcomes After Laparoscopic Resection for Colorectal Liver Metastases: A Propensity Score-based Analysis. Ann Surg, 2015, 262: 794-802. [7] James MI, Iwuji C, Irving G, et al. Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy. Cancer Lett, 2015, 364: 135-141. [8] Shady W, Petre EN, Vakiani E, et al. Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases. Oncotarget, 2017, 8: 66117-66127. |